BSTG News and Press, Biostage From 11/15/22

Biostage, Inc. (BSTG) Q3 2022 Earnings Conference Call November 15, 2022 9:00 AM Company Participants David Green - Interim Chief Executive Officer Joe Damasio - Chief Financial Officer Conference Call Participants Presentation Operator Gr...

Biostage press release ( OTC:BSTG ): Q3 GAAP EPS of -$0.10. For further details see: Biostage GAAP EPS of -$0.10

Biostage Reports Corporate Highlights and Third Quarter Financial Results PR Newswire HOLLISTON, Mass. , Nov. 14, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful fir...

Biostage Schedules Conference Call and Webcast for Q3 2022 Results PR Newswire HOLLISTON, Mass. , Nov. 10, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-...

Biostage ( OTC:BSTG ), which is developing regeneration therapies for damaged organs, has disclosed terms for a proposed $6M public offering and uplisting to Nasdaq. The Mass.-based biotech company said in a filing that it is looking at offering 1M units for the assumed pric...

Biostage Receives U.S. Patent for Cellularized Patch-Based Scaffolds for Organ Repair PR Newswire Extends core IP from tubes to patches and from regenerating the esophagus after esophagectomy to treating fistulas and strictures anywhere in the GI tract including the es...

Biostage ( OTC:BSTG ) said Monday it appointed Joseph Damasio as CFO . Damasio's recent experience includes CFO, VP finance and controller roles at Inhibikase Therapeutics, Cue Biopharma and Pressure Biosciences. For further details see: Biostage appoints Joseph Dama...

Biostage Announces Appointment of New Chief Financial Officer PR Newswire HOLLISTON, Mass. , Aug. 8, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human e...

Biostage press release ( OTC:BSTG ): Q2 GAAP EPS of -$0.12. As of June 30, 2022, the Company had operating cash on-hand of $4.6 million. For further details see: Biostage GAAP EPS of -$0.12

Biostage Reports Corporate Highlights and Second Quarter Financial Results PR Newswire HOLLISTON, Mass. , Aug. 4, 2022 /PRNewswire/ --Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful fir...